Beacon Financial Group trimmed its holdings in Pfizer Inc. (NYSE:PFE – Get Rating) by 1.1% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 29,087 shares of the biopharmaceutical company’s stock after selling 332 shares during the period. Beacon Financial Group’s holdings in Pfizer were worth $1,214,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors have also made changes to their positions in PFE. Front Street Capital Management Inc. boosted its holdings in shares of Pfizer by 4.3% in the first quarter. Front Street Capital Management Inc. now owns 5,168 shares of the biopharmaceutical company’s stock valued at $268,000 after purchasing an additional 215 shares during the period. Cape Cod Five Cents Savings Bank lifted its holdings in Pfizer by 0.7% during the third quarter. Cape Cod Five Cents Savings Bank now owns 32,775 shares of the biopharmaceutical company’s stock worth $1,435,000 after buying an additional 225 shares during the period. Synergy Asset Management LLC lifted its holdings in Pfizer by 3.3% during the fourth quarter. Synergy Asset Management LLC now owns 7,287 shares of the biopharmaceutical company’s stock worth $373,000 after buying an additional 236 shares during the period. Motco lifted its holdings in Pfizer by 0.8% during the fourth quarter. Motco now owns 31,376 shares of the biopharmaceutical company’s stock worth $1,608,000 after buying an additional 236 shares during the period. Finally, Alterity Financial Group LLC lifted its holdings in Pfizer by 4.6% during the fourth quarter. Alterity Financial Group LLC now owns 5,474 shares of the biopharmaceutical company’s stock worth $280,000 after buying an additional 243 shares during the period. 67.80% of the stock is currently owned by hedge funds and other institutional investors.
Pfizer Price Performance
Shares of PFE opened at $38.30 on Monday. The business’s 50-day moving average is $38.71 and its two-hundred day moving average is $42.62. The company has a market capitalization of $216.22 billion, a P/E ratio of 7.54, a P/E/G ratio of 1.27 and a beta of 0.64. The company has a debt-to-equity ratio of 0.31, a quick ratio of 1.11 and a current ratio of 1.37. Pfizer Inc. has a fifty-two week low of $36.17 and a fifty-two week high of $54.93.
Pfizer Announces Dividend
The business also recently declared a quarterly dividend, which will be paid on Tuesday, September 5th. Shareholders of record on Friday, July 28th will be given a dividend of $0.41 per share. This represents a $1.64 annualized dividend and a yield of 4.28%. The ex-dividend date of this dividend is Thursday, July 27th. Pfizer’s dividend payout ratio is currently 32.28%.
Insiders Place Their Bets
In related news, Director Scott Gottlieb purchased 1,000 shares of the business’s stock in a transaction on Monday, May 8th. The shares were bought at an average cost of $38.58 per share, with a total value of $38,580.00. Following the transaction, the director now owns 6,000 shares of the company’s stock, valued at $231,480. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 0.05% of the stock is owned by insiders.
Analyst Ratings Changes
A number of research firms have weighed in on PFE. Morgan Stanley lowered their target price on Pfizer from $45.00 to $44.00 and set an “equal weight” rating for the company in a report on Monday, April 10th. Jefferies Financial Group began coverage on Pfizer in a research report on Monday, March 6th. They set a “hold” rating and a $43.00 price target on the stock. Daiwa Capital Markets downgraded Pfizer from an “outperform” rating to a “neutral” rating and set a $38.00 price target on the stock. in a research report on Thursday, May 11th. Bank of America reduced their price target on Pfizer from $50.00 to $45.00 and set a “neutral” rating on the stock in a research report on Friday, April 21st. Finally, Barclays reduced their price target on Pfizer from $43.00 to $40.00 in a research report on Wednesday, May 3rd. Nine research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Pfizer presently has an average rating of “Hold” and a consensus price target of $47.33.
Pfizer Company Profile
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
- Get a free research report on Pfizer from StockNews.com
- MarketBeat Week in Review – 6/19 – 6/23
- CarMax Stock Flying On Earnings Beat, Return Of The Highs?
- Commercial Metals Company Shakes Off The Rust: Confirms Uptrend
- Smith & Wesson, A Timeless Value Play At Decade Lows
- Five stocks we like better than Pfizer
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE – Get Rating).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.
